Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02090504
Other study ID # GATE-I
Secondary ID
Status Completed
Phase Phase 4
First received March 17, 2014
Last updated March 17, 2014
Start date February 2002
Est. completion date May 2009

Study information

Verified date March 2014
Source Catholic University of the Sacred Heart
Contact n/a
Is FDA regulated No
Health authority European Union: European Medicines Agency
Study type Interventional

Clinical Trial Summary

Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. Aim of this phase IV, multicenter randomized double-blind, double dummy study is to evaluate the efficacy of SMO in comparison to oxazepam in the treatment of alcohol withdrawal symptoms (AWS).


Description:

This is a phase IV, multicenter randomized (1:1), active drug-controlled study (double-blind, double dummy) with parallel groups evaluating the efficacy of SMO versus oxazepam in the treatment of AWS in alcohol-dependent patients.

A placebo-controlled design was considered but excluded, given that a gold standard treatment for AWS is available (i.e., BDZs).

Furthermore, considering that SMO and oxazepam have two different pharmaceutical formulation (suspension and tablets, respectively), a double-dummy design was adopted.

Thus, all subjects will receive both medications, tablets (oxazepam or placebo) and suspension (SMO or placebo), at the same time.


Recruitment information / eligibility

Status Completed
Enrollment 127
Est. completion date May 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Both
Age group 21 Years to 75 Years
Eligibility Inclusion Criteria:

- age range 21-75,

- diagnosis of alcohol dependence according to DSM-IV criteria

- the presence of AWS as assessed by Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale, a scoring system for quantitative evaluation of physical symptoms of AWS.20 Only subjects with a CIWA-Ar score equal to or higher than 10 (defined as moderate or severe AWS requiring pharmacological treatment) were ultimately enrolled in the study.

Exclusion criteria:

- =55 kg of body weight;

- history of withdrawal fits within 24 hours pre-study;

- history of epilepsy or epileptics seizures not properly controlled by established anti-epileptic treatment;

- dependence from narcotics, BDZs or other drugs of abuse;

- documented pre-existent hypersensitivity to SMO or to BDZs,

- renal failure (blood creatinine >2•5 mg/dl and/or documented proteinuria >500 mg/die),

- heart failure,

- severe respiratory failure

- hepatic encephalopathy stage II-IV;

- psychiatric disorders requiring treatment with psychoactive medications before the start of the study;

- treatment with clonidine, haloperidol, bromocriptine during the last 3 months prior to participation in the study;

- participation to other clinical investigations in the previous month prior to recruitment;

- females whose could not assure not to become pregnant during the 1 month period of treatment, and during the subsequent 3 weeks;

- subjects without a stable social condition or homeless.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Sodium Oxybate (SMO)

Oxazepam


Locations

Country Name City State
Austria University of Wien Wien AT
Italy "G. Fontana" Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Clinical Medicine, University of Bologna Bologna BO
Italy Catholic University of Rome Rome Rm

Sponsors (4)

Lead Sponsor Collaborator
Catholic University of the Sacred Heart CT Pharmaceutical Industries, Sanremo - Italy, Medical University of Vienna, University of Bologna

Countries where clinical trial is conducted

Austria,  Italy, 

References & Publications (1)

Skala K, Caputo F, Mirijello A, Vassallo G, Antonelli M, Ferrulli A, Walter H, Lesch O, Addolorato G. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014 Feb;15(2):245-57. doi: 10.1517/14656566.2014.863278. Epub 2013 Nov 28. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Craving for study drug. Assessment of craving for the study drug. day 1, day 10, day 20 No
Primary Efficacy of GHB compared to oxazepam on alcohol withdrawal symptoms The primary outcome was the reduction of symptoms of AWS reflected by the course of the total CIWA-Ar scores from the start (baseline) to the end of the study (day 10) and to the end of follow up (day 20, 10 days after drugs discontinuation). day 1, day 10, day 20 No
Secondary Course of alcohol abstinence Secondary outcome variables included the course of alcohol abstinence. In order to confirm daily alcohol abstinence, a breath analyzer was used. In addition, to define those subjects remaining abstinent throughout the whole treatment period, carbohydrate-deficient transferrin (%CDT) was evaluated at the time of screening and at the end of the treatment period. day 1, day 10, day 20 Yes
See also
  Status Clinical Trial Phase
Completed NCT02901041 - Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism Phase 3
Completed NCT03340051 - Remote Alcohol Monitoring and Episodic Thinking N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Completed NCT02486900 - Neurofeedback & Alcohol Dependence N/A
Completed NCT02705898 - Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women N/A
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02197598 - Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use Phase 4
Recruiting NCT02385643 - The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients N/A
Completed NCT01828866 - Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT02193204 - Chronic Alcohol, Stress Inflammatory Response and Relapse Risk N/A
Completed NCT01342549 - Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Phase 3
Completed NCT01165541 - A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency Phase 2
Completed NCT01176591 - HBPL Study of the Impact of the NK1 Antagonist Aprepitant Phase 2
Completed NCT00585780 - Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse Phase 1/Phase 2
Completed NCT01056484 - Mindfulness Meditation for Health Phase 2
Completed NCT00607620 - Disseminating Organizational SBI Services at Trauma Centers N/A
Completed NCT00884884 - Aripiprazole and Topiramate on Free-Choice Alcohol Use Phase 2/Phase 3
Completed NCT00463346 - Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism Phase 3